Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teriparatide and Zoledronic Acid in Osteogenesis Imperfecta
NCT01679080Phase 2Terminated
- Sponsor
- Aarhus University
- Start
- Nov 2012
- Primary completion
- Jul 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in osteogenesis imperfecta (OI) comparing Zoledronic acid + Placebo PTH, Teriparatide -> Zoledronic acid and Observation (3 arms). Primary endpoint: Bone Mineral Density at 3 years. Started Nov 2012; status: terminated.
02
Drugs
teriparatide
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on NCT01679080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01679080.